André Luis Menezes Carvalho

Dr. André Luis Menezes Carvalho


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
PDF file
ACAndré Luis Menezes Carvalho
André Luis Menezes Carvalho
RLRamon Weyler Duarte Leopoldino
Ramon Weyler Duarte Leopoldino
JSJose Eduardo Gomes da Silva
Jose Eduardo Gomes da Silva
CCClemilton Pereira da Cunha
Clemilton Pereira da Cunha
A hipertensão arterial e o diabetes mellitus estão entre as doenças crônicas mais prevalentes no Brasil. Em decorrência disso, em 2002, foi criado o Plano de Reorganização da Atenção à Hipertensão Arterial e Diabetes Mellitus. O presente estudo objetivou avaliar o perfil socioeconômico e a adesão terapêutica dos usuários cadastrados no Programa Hiperdia no município de Teresina (PI). Esta pesquisa foi desenvolvida nas Unidades Básicas de Saúde, onde foi aplicado um questionário a 400 pessoas, avaliando-se sua adesão através dos testes de Batalla e Morisky-Green. O perfil socioeconômico dos entrevistados foi o seguinte: idosos, mulheres, casados, com 1 a 4 anos de estudo, aposentados e assalariados; destes, a maioria são hipertensos. Apenas 22,50% dos hipertensos e 30,70% dos diabéticos foram consideradas aderentes segundo Batalla e de todos apenas 26,75% foram aderentes, segundo Morisky-Green. Não houve associação entre as variáveis sociodemográficas-clínicas e a adesão segundo Morisky-Green, no entanto houve associação com o tipo de morbidade apresentada. Diante desses resultados, a educação em saúde torna-se a principal estratégia para melhorar a adesão dos usuários, como também a participação de profissionais na Equipe Saúde da Família, como: o farmacêutico, o nutricionista e o educador físico.

4 November 2020 in AAPS PharmSciTech
Verified
Journal Article
Closed access
MNMarcondes Cavalcante Santana Neto
Marcondes Cavalcante Santana Neto
MCMarina Lua Vieira de Abreu Costa
Marina Lua Vieira de Abreu Costa
PFPaulo Henrique da Silva Fialho
Paulo Henrique da Silva Fialho
GLGlaucia Lais Nunes Lopes
Glaucia Lais Nunes Lopes
KFKayo Alves Figueiredo
Kayo Alves Figueiredo
ACAndré Luis Menezes Carvalho
André Luis Menezes Carvalho

1 February 2024 in OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA
Verified
Journal Article
Open access
PDF file
VLValéria Maria Sousa Leitão
Valéria Maria Sousa Leitão
MLMarcos Valério Vieira Lyrio
Marcos Valério Vieira Lyrio
GVGabriela Vanini
Gabriela Vanini
CCCarolina Borges Cordeiro
Carolina Borges Cordeiro
MOMatheus Filipe Leitão De Oliveira
Matheus Filipe Leitão De Oliveira
MNMaria Do Desterro Soares Brandão Do Nascimento
Maria Do Desterro Soares Brandão Do Nascimento
Fungi have been recognized as a great source of bioactive metabolites with great medical and pharmaceutical applicability. The objective of this work was to produce a fungal extract from Rhizopus spp and identify the secondary metabolites obtained, followed by preparation of a microemulsion formulated with Rhizopus sp extract; characterizing its antioxidant and antimicrobial activity. Among the metabolites obtained, sorbitol, linoleic acid, oleic acid, palmitic acid, and stearic acid stand out. The formulated microemulsion proved to be an effective pharmacological presentation in preserving the metabolites obtained from the fungal extract, and also potentiating in relation to the extract, when comparing the antioxidant activity and antimicrobial action.

28 September 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MNMatheus Oliveira Do Nascimento
Matheus Oliveira Do Nascimento
LDLeandro de Sousa Dias
Leandro de Sousa Dias
AMAllan Kayk Sales Meneses
Allan Kayk Sales Meneses
SLSidney De Lima
Sidney De Lima
CMCarla Veron̂ica Rodarte De Moura
Carla Veron̂ica Rodarte De Moura
ACAndré Luis Menezes Carvalho
André Luis Menezes Carvalho
Background/Objectives: The increasing incidence of invasive fungal infections and the emergence of antifungal resistance have limited the effectiveness of conventional therapies against Candida spp. This study aimed to develop and optimize nanostructured lipid carriers (NLCs) containing fluconazole (FLC) and Riparin B (RIP) using a systematic Quality-by-Design (QbD) approach. Methods: The optimized NLCs were characterized by particle size, polydispersity index (PDI), zeta potential, DSC, and FTIR analyses. Molecular docking was used as a complementary exploratory approach to investigate possible interactions of RIP with representative components of the lipid matrix and with fungal resistance-associated proteins. Release profiles and antifungal activity against Candida spp. were also evaluated. Results: The optimized NLCs exhibited a mean particle size of 144.9 ± 2.25 nm, PDI of 0.153 ± 0.03, and zeta potential of −27.8 ± 1.81 mV. DSC and FTIR analyses supported the structural organization of the lipid matrix and the formation of an imperfect crystalline network, providing structural defects favorable for the incorporation of the active compounds. RIP exhibited more favorable predicted interactions than FLC within the specific lipid configuration evaluated, although these docking scores should not be interpreted as direct thermodynamic measurements of drug–lipid affinity or as quantitative predictors of encapsulation efficiency. Docking analyses with MdR1, CdR1, and CdR2 identified possible interactions of RIP with these resistance-associated proteins, providing a structural hypothesis that may contribute to understanding the potentiation of FLC activity. However, these computational results do not establish direct efflux-pump inhibition. Release profiles followed distinct kinetic regimes, consistent with matrix relaxation for RIP and Fickian diffusion for FLC. Although RIP alone did not exhibit relevant antifungal activity, its association with FLC potentiated FLC activity against Candida spp., while incorporation of the combination into NLCs produced a further enhancement, significantly reducing the minimum inhibitory concentration. Conclusions: These findings indicate that the optimized NLC platform can enhance the antifungal performance of the FLC–RIP combination and provide a formulation framework for further investigation of this co-delivery strategy.

3 August 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
LSLeandro Josual da Costa Santos
Leandro Josual da Costa Santos
ÉAÉrika de Araújo Abi-Chacra
Érika de Araújo Abi-Chacra
RCRita de Cássia Vianna de Carvalho
Rita de Cássia Vianna de Carvalho
LFLucas Malaquias França
Lucas Malaquias França
DNDenise Andrade do Nascimento
Denise Andrade do Nascimento
ACAndré Luis Menezes Carvalho
André Luis Menezes Carvalho
This study investigated the repurposing potential of clomiphene citrate as a topical therapeutic candidate for tegumentary leishmaniasis (TL) and candidiasis. Comparative in silico analyses were performed to evaluate absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties in comparison with meglumine antimoniate and amphotericin B. In addition, molecular docking was conducted to investigate the interaction of clomiphene with Leishmania spp. arginase and the Sap5 protease of Candida albicans. Clomiphene exhibited a favorable physicochemical profile, characterized by high lipophilicity, moderate skin permeability, and predicted oral bioavailability and intestinal absorption superior to those of the reference drugs. Toxicological predictions also indicated a lower systemic toxicity profile compared with conventional therapies. Molecular docking revealed favorable binding energies and interactions with key residues within the active sites of both targets. Experimental assays demonstrated that clomiphene inhibited the early stages of C. albicans biofilm formation and exhibited potent leishmanicidal activity against L. amazonensis promastigotes, with a high selectivity index in macrophages. Together, these findings indicate that clomiphene citrate represents a promising candidate for further investigation as a potential therapeutic agent against tegumentary leishmaniasis and candidiasis.

15 November 2017
Verified
Conference Paper
Closed access
ALAmanda Thaís dos Santos Leite
Amanda Thaís dos Santos Leite
GLGláucia Laís Nunes Lopes
Gláucia Laís Nunes Lopes
ACAndré Luis Menezes Carvalho
André Luis Menezes Carvalho
LLLuzia Kalyne Almeida Moreira Leal
Luzia Kalyne Almeida Moreira Leal